Search Result

Results for "

CGRP+Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenylate Cyclase (1) Amylin Receptor (4) CGRP Receptor (34) Cytochrome P450 (1) Epigenetic Reader Domain (1) ERK (1) Isotope-Labeled Compounds (3) Reference Standards (2)
By Research Areas:	Cardiovascular Disease (10) Endocrinology (2) Infection (1) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (26)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15498

Rimegepant Maximum Cited Publications 10 Publications Verification BMS-927711; BHV-3000	CGRP Receptor	Neurological Disease
Rimegepant (BMS-927711) is an orally bioavailable and blood-brain barrier permeable antagonist of *CGRP* and AMY1 receptors, with a pIC₅₀ of 8.01 and a K_i of 0.027 nM for human *CGRP* receptors. Rimegepant antagonizes cAMP production induced by αCGRP, βCGRP and amylin at *CGRP* and AMY1 receptors in humans, rats and mice, as well as at rat AMY3 receptors. Rimegepant can be used in research related to migraine .

HY-12366

Ubrogepant MK-1602	CGRP Receptor	Cardiovascular Disease Neurological Disease
Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for *CGRP* receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by *α-CGRP*. Ubrogepant can be used in the study of acute migraine .

HY-10301

MK-3207 5 Publications Verification	CGRP Receptor	Neurological Disease
MK-3207 is an orally active, highly selective and species-specific *CGRP receptor* antagonist (for human *CGRP receptor: IC₅₀=0.12 nM; K_i*=0.024 nM). MK-3207 can be used for migraine studies .

HY-P1393

AC 187	Amylin Receptor	Endocrinology
AC 187 is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 has neuroprotective effects .

HY-P1471

Adrenomedullin (AM) (22-52), human 4 Publications Verification 22-52-Adrenomedullin (human)	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist, and also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .

HY-32709

Telcagepant 2 Publications Verification MK-0974	CGRP Receptor	Neurological Disease
Telcagepant (MK-0974) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist with K_is of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.

HY-P0209

*Rat CGRP-(8-37)* Maximum Cited Publications 9 Publications Verification	CGRP Receptor	Cardiovascular Disease Neurological Disease
Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective *CGRP receptor* antagonist.

HY-134992

Vazegepant Zavegepant; BHV-3500	CGRP Receptor	Neurological Disease
Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist. Vazegepant can be used in the study of migraine .

HY-P9938

Erenumab 1 Publications Verification AMG-334	CGRP Receptor	Neurological Disease
Erenumab (AMG-334) is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene-related peptide (CGRP) receptor. Erenumab prevents the increase in dermal blood flow in cynomolgus monkeys. Erenumab can be used in the research of episodic migraine .

HY-P1014

HCGRP-(8-37) 2 Publications Verification Human α-CGRP (8-37)	CGRP Receptor	Cardiovascular Disease
HCGRP-(8-37) (Human α-CGRP (8-37)) is a fragment of human calcitonin gene-related peptide (hCGRP) and an antagonist of the *CGRP* receptor, with an IC₅₀ of 32.1 pM against the *CGRP* receptor. HCGRP-(8-37) blocks adenylate cyclase activation induced by *CGRP* receptor ligands and attenuates vascular responses triggered by *CGRP. HCGRP-(8-37) reduces capsaicin-induced vasodilation in porcine nasal mucosa and superficial skin. HCGRP-(8-37) serves as a research tool to distinguish effects mediated by CGRP* or calcitonin receptors, and to investigate *CGRP*-induced vascular effects .

HY-15498A

Rimegepant sulfate hydrate Maximum Cited Publications 10 Publications Verification BMS-927711 sulfate hydrate; BHV-3000 sulfate hydrate	CGRP Receptor	Neurological Disease
Rimegepant (BMS-927711) sulfate hydrate is a potent, orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a K_i of 0.027 nM and an IC₅₀ of 0.14 nM for hCGRP receptor. Rimegepant sulfate hydrate can be used for migraine research .

HY-P99017

Eptinezumab ALD-403	CGRP Receptor	Neurological Disease
Eptinezumab (ALD-403) is a human monoclonal antibody targeting the α and β subtypes of human calcitonin gene-related peptide (CGRP). Eptinezumab binds to the *CGRP* ligand and blocks its binding to endogenous *CGRP* receptors, thereby inhibiting receptor activation. Eptinezumab can be used in research related to migraine .

HY-112262

CGRP antagonist 1	CGRP Receptor	Cardiovascular Disease Neurological Disease
CGRP antagonist 1 (compound 21) is a highly potent *CGRP receptor* antagonist with a K_i and an IC₅₀ of 1.7 nM and 5.7 nM, respectively .

HY-10302

MK-3207 Hydrochloride 5 Publications Verification	CGRP Receptor	Neurological Disease
MK-3207 (Hydrochloride) is a potent and orally bioavailable *CGRP receptor* antagonist with IC₅₀ of 0.12 nM and K_i of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3.

HY-P1913A

Calcitonin Gene Related Peptide II (rat) TFA 1 Publications Verification CGRP II (rat) TFA	CGRP Receptor	Cardiovascular Disease
Calcitonin Gene Related Peptide II rat TFA, a *CGRP receptor* activator, is a potent and long-lasting vasodilator. Calcitonin Gene Related Peptide II rat TFA can be used in the research of cardiovascular diseases .

HY-P1393A

AC 187 TFA	Amylin Receptor	Endocrinology
AC 187 TFA is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 TFA shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 TFA has neuroprotective effects .

HY-117694

MK-8825	CGRP Receptor	Neurological Disease Inflammation/Immunology
MK-8825 is an orally active, selective *CGRP* receptor antagonist with a K_i value of 47 pM for human *CGRP* receptors and 17 nM for rat *CGRP* receptors. MK-8825 blocks *CGRP*-stimulated cAMP responses and exhibits competitive-like antagonism. MK-8825 can be used in the research of migraine and temporomandibular joint disorders .

HY-P11320

Davalintide	Amylin Receptor CGRP Receptor	Metabolic Disease
Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC₅₀ = 0.04 nM), calcitonin receptor (IC₅₀ = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC₅₀ = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC₅₀ = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .

HY-103304

SB 268262	Others	Neurological Disease
CGRP antagonist 4 is an antagonist of calcitonin gene-related peptide (CGRP) receptor. CGRP antagonist 4 shows the highest affinity for CGRP receptors in the human brain. CGRP antagonist 4 can be used to study the binding properties of non-peptide calcitonin gene-related peptide (CGRP) receptor antagonist (gepants) in rat, pig and human menes .

HY-P3689

[Tyr22] Calcitonin Gene Related Peptide, (22-37), rat	CGRP Receptor Adenylate Cyclase	Others
[Tyr22] Calcitonin Gene Related Peptide, (22-37), rat is a fragments 22-37 of rat calcitonin gene related peptide (CGRP), targeting *CGRP receptor* and adenylate cyclase. Calcitonin is mainly produced by thyroid C cells while CGRP is secreted and stored in the nervous system .

HY-P1913

Calcitonin Gene Related Peptide II (rat) CGRP II (rat)	CGRP Receptor	Cardiovascular Disease
Calcitonin Gene Related Peptide II rat, a *CGRP receptor* activator, is a potent and long-lasting vasodilator. Calcitonin Gene Related Peptide II rat can be used in the research of cardiovascular diseases .

HY-145353

HTL22562	CGRP Receptor	Neurological Disease
HTL22562 is a calcitonin gene-related peptide (CGRP) receptor antagonist for acute research of migraine.

HY-114945

CGRP antagonist 2	CGRP Receptor	Neurological Disease
CGRP antagonist 2 is a *CGRP receptor* antagonist. CGRP antagonist 2 can be used for pain relief .

HY-12366R

Ubrogepant (Standard) MK-1602 (Standard)	CGRP Receptor Reference Standards	Cardiovascular Disease Neurological Disease
Ubrogepant (Standard) is the analytical standard of Ubrogepant. This product is intended for research and analytical applications. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for *CGRP* receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by *α-CGRP*. Ubrogepant can be used in the study of acute migraine .

HY-32709S

Telcagepant-d8 MK-0974-d₈	Isotope-Labeled Compounds CGRP Receptor	Neurological Disease
Telcagepant-d₈ (MK-0974-d₈) is deuterium labeled Telcagepant. Telcagepant (MK-0974) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist with K_is of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.

HY-162925

CGRP antagonist 6	CGRP Receptor	Neurological Disease
CGRP antagonist 6 (Compound 23) is a *CGRP receptor* antagonist (K_i: 0.84 nM). CGRP antagonist 6 can be used for research of migraine .

HY-114574

BMS-694153	CGRP Receptor	Neurological Disease
BMS-694153 is a potent antagonist of the human calcitonin gene-related peptide receptor (CGRP Receptor). BMS-694153 can be used for migraine with rapid and efficient intranasal exposure .

HY-134992S

(Rac)-Vazegepant-13C,d3	Isotope-Labeled Compounds	Others
(Rac)-Vazegepant- ¹³C,d₃ is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine .

HY-P1471A

Adrenomedullin (AM) (22-52), human TFA 22-52-Adrenomedullin (human) TFA	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH₂ terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitonin generelated peptide *(CGRP)* receptor in the hindlimb vascular bed of the cat .

HY-12366S

Ubrogepant-d5 MK-1602-d₅	Isotope-Labeled Compounds CGRP Receptor	Cardiovascular Disease Neurological Disease
Ubrogepant-d₅ (MK-1602-d₅) is deuterium labeled Ubrogepant. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for *CGRP* receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by *α-CGRP*. Ubrogepant can be used in the study of acute migraine .

HY-183181

CGRP antagonist-9	CGRP Receptor	Neurological Disease
CGRP antagonist-9 is a *CGRP receptor* antagonist with an IC₅₀ of 25 nM. It regulates the cAMP signaling pathway and can be used in migraine-related studies .

HY-183180

CGRP antagonist-8	CGRP Receptor	Neurological Disease
CGRP antagonist-8 is a *CGRP receptor* antagonist with an IC₅₀ of 2.7 nM. CGRP antagonist-8 can be used for the research of migraine .

HY-132131

Vazegepant hydrochloride Zavegepant hydrochloride; BHV-3500 hydrochloride	CGRP Receptor	Infection Inflammation/Immunology
Vazegepant (BHV-3500) hydrochloride is a highly affinity *CGRP* receptor antagonist (hCGRP K_i= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine. Vazegepant hydrochloride may be helpful in effective management of COVID-19 associated pulmonary inflammation .

HY-15498B

Rimegepant hemisulfate BMS-927711 hemisulfate; BHV-3000 hemisulfate	CGRP Receptor	Neurological Disease
Rimegepant (BMS-927711) hemisulfate is a potent, orally active, selective and competitive calcitonin gene-related peptide (CGRP) receptor antagonist with a K_i of 0.027 nM and an IC₅₀ of 0.14 nM for hCGRP receptor. Rimegepant hemisulfate can be used for migraine research .

HY-10302R

MK-3207 hydrochloride (Standard)	Reference Standards CGRP Receptor	Neurological Disease
MK-3207 hydrochloride (Standard) is the analytical standard of MK-3207 hydrochloride (HY-10302). This product is intended for research and analytical applications. MK-3207 hydrochloride is a potent and orally bioavailable CGRP receptor antagonist with IC₅₀ of 0.12 nM and K_i of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3.

HY-P11587

BGM1812	Amylin Receptor CGRP Receptor	Metabolic Disease
BGM1812 is a dual agonist of amylin (hAMY3R) (EC₅₀ = 0.627 nM) and *CGRP Receptor* (hCTR) (EC₅₀ = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity .

HY-179684

PCC0105005	CGRP Receptor 5-HT Receptor ERK Epigenetic Reader Domain	Neurological Disease
PCC0105005 is a dual-target *CGRP Receptor* antagonist (IC₅₀ = 1.01 nM) and a partial agonist of 5-HT1F Receptor (EC₅₀ = 77.91 nM). PCC0105005 shows significant efficacy in the rat model of migraine. PCC0105005 significantly reduces the expression of CGRP and c-Fos proteins, and inhibits the phosphorylation levels of ERK and CREB. PCC0105005 can be used for research on migraine .

HY-180955

Desfluoro-BMS-694153	CGRP Receptor Cytochrome P450	Neurological Disease
Desfluoro-BMS-694153 (Compound 3) is a calcitonin gene-related peptide receptor (CGRP receptor) antagonist, with a K_i value of 0.01 nM. Desfluoro-BMS-694153 has a significantly reduced risk of CYP3A4 inhibition, and its IC₅₀ values for CYP3A4-BFC and CYP3A4-BZR are 36 and 6 μM respectively. Desfluoro-BMS-694153 can be used for research on migraines .

Cat. No.	Product Name	Target	Research Area

HY-P1393

AC 187	Amylin Receptor	Endocrinology
AC 187 is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 has neuroprotective effects .

HY-P1471

Adrenomedullin (AM) (22-52), human 4 Publications Verification 22-52-Adrenomedullin (human)	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist, and also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat .

HY-P0209

*Rat CGRP-(8-37)* Maximum Cited Publications 9 Publications Verification	CGRP Receptor	Cardiovascular Disease Neurological Disease
Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective *CGRP receptor* antagonist.

HY-P1014

HCGRP-(8-37) 2 Publications Verification Human α-CGRP (8-37)	CGRP Receptor	Cardiovascular Disease
HCGRP-(8-37) (Human α-CGRP (8-37)) is a fragment of human calcitonin gene-related peptide (hCGRP) and an antagonist of the *CGRP* receptor, with an IC₅₀ of 32.1 pM against the *CGRP* receptor. HCGRP-(8-37) blocks adenylate cyclase activation induced by *CGRP* receptor ligands and attenuates vascular responses triggered by *CGRP. HCGRP-(8-37) reduces capsaicin-induced vasodilation in porcine nasal mucosa and superficial skin. HCGRP-(8-37) serves as a research tool to distinguish effects mediated by CGRP* or calcitonin receptors, and to investigate *CGRP*-induced vascular effects .

HY-P1913A

Calcitonin Gene Related Peptide II (rat) TFA 1 Publications Verification CGRP II (rat) TFA	CGRP Receptor	Cardiovascular Disease
Calcitonin Gene Related Peptide II rat TFA, a *CGRP receptor* activator, is a potent and long-lasting vasodilator. Calcitonin Gene Related Peptide II rat TFA can be used in the research of cardiovascular diseases .

HY-P1393A

AC 187 TFA	Amylin Receptor	Endocrinology
AC 187 TFA is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 TFA shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 TFA has neuroprotective effects .

HY-P11320

Davalintide	Amylin Receptor CGRP Receptor	Metabolic Disease
Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC₅₀ = 0.04 nM), calcitonin receptor (IC₅₀ = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC₅₀ = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC₅₀ = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .

HY-P3689

[Tyr22] Calcitonin Gene Related Peptide, (22-37), rat	CGRP Receptor Adenylate Cyclase	Others
[Tyr22] Calcitonin Gene Related Peptide, (22-37), rat is a fragments 22-37 of rat calcitonin gene related peptide (CGRP), targeting *CGRP receptor* and adenylate cyclase. Calcitonin is mainly produced by thyroid C cells while CGRP is secreted and stored in the nervous system .

HY-P1913

Calcitonin Gene Related Peptide II (rat) CGRP II (rat)	CGRP Receptor	Cardiovascular Disease
Calcitonin Gene Related Peptide II rat, a *CGRP receptor* activator, is a potent and long-lasting vasodilator. Calcitonin Gene Related Peptide II rat can be used in the research of cardiovascular diseases .

HY-P1471A

Adrenomedullin (AM) (22-52), human TFA 22-52-Adrenomedullin (human) TFA	CGRP Receptor	Cardiovascular Disease
Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH₂ terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitonin generelated peptide *(CGRP)* receptor in the hindlimb vascular bed of the cat .

HY-P11587

BGM1812	Amylin Receptor CGRP Receptor	Metabolic Disease
BGM1812 is a dual agonist of amylin (hAMY3R) (EC₅₀ = 0.627 nM) and *CGRP Receptor* (hCTR) (EC₅₀ = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9938

Erenumab 1 Publications Verification AMG-334	CGRP Receptor	Neurological Disease
Erenumab (AMG-334) is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene-related peptide (CGRP) receptor. Erenumab prevents the increase in dermal blood flow in cynomolgus monkeys. Erenumab can be used in the research of episodic migraine .

HY-P99017

Eptinezumab ALD-403	CGRP Receptor	Neurological Disease
Eptinezumab (ALD-403) is a human monoclonal antibody targeting the α and β subtypes of human calcitonin gene-related peptide (CGRP). Eptinezumab binds to the *CGRP* ligand and blocks its binding to endogenous *CGRP* receptors, thereby inhibiting receptor activation. Eptinezumab can be used in research related to migraine .

Cat. No.	Product Name	Chemical Structure

HY-32709S

Telcagepant-d8
Telcagepant-d₈ (MK-0974-d₈) is deuterium labeled Telcagepant. Telcagepant (MK-0974) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist with K_is of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.

HY-134992S

(Rac)-Vazegepant-13C,d3
(Rac)-Vazegepant- ¹³C,d₃ is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine .

HY-12366S

Ubrogepant-d5

Ubrogepant-d₅ (MK-1602-d₅) is deuterium labeled Ubrogepant. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: